Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 29 Sept 2026, 11:30 UTC. The headline in use is “Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases”. This note is SignalsMonitor's own briefing, not the publisher's article.